Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitorsFranklin L Chen, Wenle Xia, Neil L Spector
Nano Letters|October 10, 2022
Luminescent Gold Nanoparticles with Controllable Hydrophobic InteractionsBing Tang, Wenle Xia, Wei Cai, et al.
Oncogene|January 23, 2004
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Wenle Xia, Lei-Hua Liu, Peter Ho, et al.
Talanta|October 29, 2018
A ratiometric detection of heparin with high sensitivity based on aggregation-enhanced emission of gold nanoclusters triggered by silicon nanoparticlesFei Qu, Wenle Xia, Lian Xia, et al.
Breast Cancer Research and Treatment|February 27, 2003
Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cellsWenle Xia, Lys Hardy, Leihua Liu, et al.
Oncogene|August 11, 2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsWenle Xia, Catherine M Gerard, Leihua Liu, et al.
Cancer Research|February 7, 2007
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersWenle Xia, Intisar Husain, Leihua Liu, et al.
Plos One|February 20, 2014
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosisWenle Xia, David Gooden, Leihua Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2007
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cellsNeil L Spector, Yosef Yarden, Bradley Smith, et al.
Oncogene|September 6, 2002
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysWenle Xia, Robert J Mullin, Barry R Keith, et al.
Pageof 3